Ultra-rare/JJ
Disease/NN
and/CC
Genomics-Driven/JJ
Precision/NN
Medicine/NN
./.
====================
Since/IN
next-generation/JJ
sequencing/NN
(/(
NGS/NN
)/)
technique/NN
was/VBD
adopted/VBN
into/IN
clinical/JJ
practices/NNS
,/,
revolutionary/JJ
advances/NNS
in/IN
diagnosing/VBG
rare/JJ
genetic/JJ
diseases/NNS
have/VBP
been/VBN
achieved/VBN
through/IN
translating/VBG
genomic/JJ
medicine/NN
into/IN
precision/NN
or/CC
personalized/VBN
management/NN
./.
====================
Indeed/RB
,/,
several/JJ
successful/JJ
cases/NNS
of/IN
molecular/JJ
diagnosis/NN
and/CC
treatment/NN
with/IN
personalized/VBN
or/CC
targeted/VBN
therapies/NNS
of/IN
rare/JJ
genetic/JJ
diseases/NNS
have/VBP
been/VBN
reported/VBN
./.
====================
Still/RB
,/,
there/EX
are/VBP
several/JJ
obstacles/NNS
to/TO
be/VB
overcome/VBN
for/IN
wider/JJR
application/NN
of/IN
NGS-based/JJ
precision/NN
medicine/NN
,/,
including/VBG
high/JJ
sequencing/NN
cost/RB
,/,
incomplete/JJ
variant/JJ
sensitivity/NN
and/CC
accuracy/NN
,/,
practical/JJ
complexities/NNS
,/,
and/CC
a/DT
shortage/JJ
of/IN
available/JJ
treatment/NN
options/NNS
./.
====================
Next-generation/NN
sequencing/NN
(/(
NGS/NN
)/)
has/VBZ
achieved/VBN
great/JJ
advances/NNS
in/IN
medicine/JJ
and/CC
clinical/JJ
practice/NN
,/,
as/IN
well/RB
as/IN
in/IN
basic/JJ
research/NN
field/NN
./.
====================
NGS-based/VBN
precision/NN
medicine/NN
has/VBZ
mainly/RB
focused/VBN
on/IN
cancer/NN
[/(
12/CD
]/)
,/,
given/VBN
the/DT
prevalence/NN
,/,
availability/NN
of/IN
drugs/NNS
targeting/VBG
major/JJ
oncogenic/JJ
factors/NNS
,/,
and/CC
impact/NN
on/IN
human/JJ
health/NN
./.
====================
Another/DT
sector/NN
of/IN
focus/NN
through/IN
NGS-based/JJ
precision/NN
medicine/NN
is/VBZ
ultra-rare/JJ
diseases/NNS
./.
====================
Ultra-rare/JJ
diseases/NNS
can/MD
be/VB
defined/VBN
as/IN
disorders/NNS
that/DT
occur/VBP
with/IN
a/DT
prevalence/NN
of/IN
below/IN
1/CD
in/IN
2,000,000/CD
,/,
although/IN
this/DT
frequency/NN
cutoff/JJ
can/MD
be/VB
flexible/JJ
[/(
3/CD
]/)
./.
====================
Usually/RB
,/,
rare/JJ
disease/NN
research/NN
is/VBZ
performed/VBN
with/IN
large/JJ
families/NNS
for/IN
traits/VBZ
with/IN
dominant/JJ
inheritance/NN
[/(
45/CD
]/)
or/CC
patient-parent/JJ
trios/NNS
for/IN
spontaneous/JJ
cases/NNS
[/(
6/CD
]/)
./.
====================
Discovery/RB
of/IN
causative/JJ
genetic/JJ
variants/NNS
using/VBG
whole/JJ
exome/DT
sequencing/NN
(/(
WES/NNS
)/)
or/CC
whole/JJ
genome/NN
sequencing/NN
(/(
WGS/NN
)/)
should/MD
be/VB
followed/VBN
by/IN
in/FW
vitro/FW
or/CC
in/IN
vivo/FW
model/NN
functional/JJ
studies/NNS
to/TO
fully/RB
explain/VB
the/DT
molecular/JJ
basis/NN
of/IN
the/DT
diseases/NNS
and/CC
confirm/VBP
the/DT
functionality/NN
of/IN
the/DT
variants/NNS
[/(
4567/CD
]/)
./.
====================
It/PRP
is/VBZ
presumed/VBN
that/DT
a/DT
large/JJ
portion/NN
of/IN
ultra-rare/JJ
diseases/NNS
are/VBP
caused/VBN
by/IN
de/FW
novo/FW
mutations/NNS
occurring/VBG
at/IN
functionally/RB
important/JJ
protein/NN
coding/VBG
regions/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
[/(
8/CD
9/CD
]/)
./.
====================
Every/RB
human/JJ
zygote/NN
is/VBZ
expected/VBN
to/TO
have/VB
approximately/RB
70â€“80/CD
de/FW
novo/FW
mutations/NNS
in/IN
its/PRP$
genome/NN
,/,
and/CC
this/DT
poses/VBZ
a/DT
small/JJ
chance/NN
to/TO
have/VB
ultra-rare/RB
diseases/NNS
,/,
depending/VBG
on/IN
the/DT
position/NN
where/WRB
the/DT
de/FW
novo/FW
mutations/NNS
lie/VBP
[/(
810/CD
]/)
./.
====================
Since/IN
NGS/NN
was/VBD
adopted/VBN
into/IN
medical/JJ
genetics/NNS
,/,
the/DT
number/NN
of/IN
rare/JJ
disease-causing/VBG
gene/NN
discoveries/VBZ
has/VBZ
been/VBN
increasing/VBG
rapidly/RB
,/,
and/CC
the/DT
genetics/NNS
of/IN
many/JJ
idiopathic/JJ
diseases/NNS
have/VBP
been/VBN
elucidated/VBN
[/(
111213/CD
]/)
./.
====================
In/IN
this/DT
review/NN
,/,
we/PRP
present/VBP
the/DT
perspectives/NNS
gained/VBN
from/IN
recent/JJ
studies/NNS
on/IN
ultra-rare/JJ
diseases/NNS
diagnosed/VBD
by/IN
NGS/NN
and/CC
successful/JJ
treatments/NNS
and/CC
discuss/VBP
the/DT
potential/JJ
obstacles/NNS
for/IN
wider/JJR
application/NN
of/IN
NGS-based/JJ
precision/NN
medicine/NN
./.
====================
Although/IN
cystic/JJ
fibrosis/NN
is/VBZ
not/RB
an/DT
ultra-rare/JJ
disease/NN
by/IN
definition/NN
,/,
it/PRP
presents/VBZ
a/DT
good/JJ
example/NN
of/IN
precision/NN
medicine/NN
./.
====================
Typically/RB
inherited/VBN
in/IN
an/DT
autosomal/JJ
recessive/JJ
manner/NN
,/,
patients/NNS
carry/VBP
two/CD
non-functional/JJ
alleles/NNS
of/IN
cystic/JJ
fibrosis/NN
transmembrane/JJ
conductance/NN
regulator/NN
(/(
CFTR/NN
)/)
./.
====================
Recently/RB
,/,
an/DT
NGS-based/JJ
diagnostic/JJ
assay/NN
to/TO
detect/VB
mutations/NNS
in/IN
CFTR/NN
was/VBD
authorized/VBN
for/IN
marketing/VBG
by/IN
the/DT
United/JJ
States/NNS
Food/NN
and/CC
Drug/NN
Administration/NN
(/(
FDA/NN
)/)
[/(
14/CD
]/)
./.
====================
In/IN
addition/NN
,/,
ivacaftor/CC
(/(
Kalydeco/NNP
,/,
Vertex/NNP
Pharmaceuticals/NNS
,/,
Cambridge/NNP
,/,
MA/NN
,/,
USA/NNP
)/)
,/,
a/DT
potentiator/NN
of/IN
CFTR/NN
,/,
and/CC
lumacaftor/NN
(/(
Orkambi/NNP
,/,
Vertex/NNP
Pharmaceuticals/NNS
;/:
combination/NN
drug/NN
with/IN
ivacaftor/DT
)/)
,/,
a/DT
corrector/NN
of/IN
CFTR/NN
,/,
were/VBD
approved/VBN
by/IN
the/DT
FDA/NN
for/IN
the/DT
treatment/NN
of/IN
cystic/JJ
fibrosis/NN
patients/NNS
with/IN
nonsynonymous/JJ
mutations/NNS
(/(
http/RB
:/:
//www.kalydeco.com/IN
)/)
and/CC
the/DT
F508del/NN
mutation/NN
(/(
http/RB
:/:
//www.orkambi.com/IN
)/)
,/,
respectively/RB
[/(
15/CD
]/)
./.
====================
NGS-based/VBN
assays/NNS
have/VBP
made/VBN
it/PRP
possible/JJ
to/TO
detect/VB
certain/JJ
mutations/NNS
that/WDT
can/MD
be/VB
successfully/RB
treated/VBN
by/IN
mutation-specific/JJ
drugs/NNS
(/(
Table/JJ
1/CD
)/)
[/(
16/CD
]/)
./.
====================
The/DT
famous/JJ
case/NN
of/IN
Nick/NN
Volker/NN
exemplifies/VBZ
the/DT
beneficial/JJ
effect/NN
of/IN
NGS/NN
techniques/NNS
on/IN
patients/NNS
with/IN
atypical/JJ
and/CC
undiagnosed/VBD
disorders/NNS
[/(
17/CD
]/)
./.
====================
The/DT
cause/JJ
of/IN
his/DT
fatal/JJ
bowel/NN
inflammation/NN
and/CC
colocutaneous/JJ
fistula/NN
turned/JJ
out/IN
to/TO
be/VB
a/DT
mutation/NN
in/IN
the/DT
X-linked/JJ
inhibitor/NN
of/IN
apoptosis/NN
protein/NN
(/(
XIAP/NN
)/)
gene/NN
by/IN
WES/NN
,/,
which/WDT
has/VBZ
important/JJ
roles/NNS
in/IN
inflammatory/JJ
signaling/NN
and/CC
immunity/NN
./.
====================
His/NN
disease/NN
was/VBD
almost/RB
cured/VBN
by/IN
cord/NN
blood/NN
transplantation/NN
./.
====================
Following/VBG
this/DT
,/,
a/DT
few/JJ
more/RBR
cases/NNS
of/IN
precision/NN
medicine/NN
supported/VBD
by/IN
NGS/NN
have/VBP
been/VBN
reported/VBN
./.
====================
WGS/NN
of/IN
14-year-old/JJ
twins/NNS
with/IN
dopa/NN
(/(
3,4-dihydroxyphenylalanine/NN
)/)
-responsive/JJ
dystonia/NN
revealed/VBD
compound/NN
heterozygous/JJ
mutations/NNS
in/IN
the/DT
sepiapterin/NN
reductase/NN
(/(
SPR/NN
)/)
gene/NN
,/,
encoding/VBG
sepiapterin/NN
reductase/NN
./.
====================
Disruption/NN
of/IN
the/DT
enzyme/NN
caused/VBD
a/DT
decrease/NN
in/IN
the/DT
neurotransmitters/NNS
dopamine/NN
and/CC
serotonin/NN
,/,
and/CC
administration/NN
of/IN
L-dopa/NN
with/IN
5-hydroxytryptophan/JJ
,/,
a/DT
serotonin/NN
precursor/NN
,/,
led/VBD
to/TO
clinical/JJ
improvements/NNS
in/IN
both/DT
twins/NNS
[/(
18/CD
]/)
./.
====================
Another/DT
case/NN
was/VBD
a/DT
cancer/NN
:/:
the/DT
serine/threonine/NN
protein/NN
kinase/NN
B-raf/NN
(/(
BRAF/NN
)/)
V600E/NN
mutation/NN
in/IN
metastatic/JJ
rhabdoid/NN
meningioma/NN
was/VBD
found/VBN
by/IN
targeted/VBN
NGS/NN
in/IN
a/DT
6-year-old/JJ
girl/JJ
[/(
19/CD
]/)
./.
====================
She/PRP
was/VBD
successfully/RB
treated/VBN
with/IN
dabrafenib/NN
,/,
a/DT
BRAF/NN
inhibitor/NN
./.
====================
Most/JJS
recently/RB
,/,
a/DT
more/RBR
dramatic/JJ
case/NN
was/VBD
of/IN
a/DT
14-year-old/JJ
girl/JJ
who/WP
had/VBD
suffered/VBN
from/IN
autoimmune/JJ
enteropathy/NN
since/IN
she/PRP
was/VBD
3/CD
months/NNS
old/JJ
[/(
6/CD
]/)
./.
====================
A/DT
novel/JJ
de/FW
novo/FW
mutation/NN
in/IN
the/DT
ligand/NN
binding/NN
domain/NN
of/IN
cytotoxic/JJ
T/NN
lymphocyte/NN
antigen/NN
4/CD
(/(
CTLA-4/NN
)/)
was/VBD
discovered/VBN
by/IN
WES/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
[/(
62021/CD
]/)
./.
====================
The/DT
mutation/NN
was/VBD
presumed/VBN
to/TO
be/VB
causative/JJ
after/IN
several/JJ
in/IN
vitro/FW
immunological/JJ
experiments/NNS
./.
====================
Abatacept/IN
,/,
an/DT
FDA-approved/JJ
fusion/NN
protein/NN
of/IN
the/DT
extracellular/JJ
domain/NN
of/IN
CTLA-4/NN
and/CC
the/DT
Fc/NN
region/NN
of/IN
immunoglobulin/NN
for/IN
rheumatoid/JJ
arthritis/NN
,/,
was/VBD
administered/VBN
to/TO
the/DT
patient/NN
and/CC
restored/VBD
regulatory/JJ
T/NN
cell/NN
function/NN
./.
====================
Clinically/RB
,/,
treatment/NN
with/IN
abatacept/IN
without/IN
the/DT
need/NN
for/IN
other/JJ
immunosuppressants/NNS
reduced/VBD
diarrhea/NN
output/RB
by/IN
about/RB
67/CD
%/NN
(/(
from/IN
3/CD
L/day/JJ
to/TO
1/CD
L/day/NN
)/)
./.
====================
Markedly/RB
,/,
blood/NN
transfusion/NN
was/VBD
not/RB
necessary/JJ
anymore/DT
,/,
allowing/VBG
the/DT
patient/NN
to/TO
be/VB
discharged/VBN
from/IN
a/DT
3-year-long/JJ
hospitalization/NN
,/,
merely/RB
needing/VBG
partial/JJ
parenteral/JJ
nutrition/NN
./.
====================
Prenatal/JJ
screening/NN
and/CC
prediction/NN
of/IN
ultra-rare/JJ
disease/NN
with/IN
NGS/NN
are/VBP
not/RB
widely/RB
used/VBN
yet/RB
due/JJ
to/TO
their/PRP$
cost/JJ
and/CC
efficacy/NN
./.
====================
But/CC
,/,
if/IN
the/DT
parents/NNS
of/IN
a/DT
child/JJ
with/IN
an/DT
ultra-rare/JJ
disease/NN
who/WP
was/VBD
diagnosed/VBN
by/IN
NGS/NN
plan/NN
to/TO
have/VB
another/DT
child/JJ
,/,
prenatal/JJ
testing/NN
with/IN
DNA/NN
extracted/VBN
from/IN
chorionic/JJ
villus/FW
sampling/JJ
or/CC
amniocentesis/NN
is/VBZ
possible/JJ
./.
====================
If/IN
the/DT
cost/JJ
of/IN
NGS/NN
declines/VBZ
,/,
screening/NN
of/IN
rare/JJ
genetic/JJ
diseases/NNS
with/IN
NGS/NN
might/MD
be/VB
routinely/RB
performed/VBN
./.
====================
At/IN
this/DT
moment/NN
,/,
a/DT
non-invasive/JJ
prenatal/JJ
test/NN
using/VBG
NGS/NN
is/VBZ
rapidly/RB
being/VBG
introduced/VBN
to/TO
the/DT
clinical/JJ
field/NN
,/,
which/WDT
allows/VBZ
the/DT
detection/NN
of/IN
fetal/JJ
aneuploidies/NNS
,/,
such/JJ
as/IN
trisomy/NN
21/CD
(/(
Down/NN
syndrome/NN
)/)
[/(
22/CD
]/)
./.
====================
This/DT
technique/NN
uses/VBZ
cell-free/JJ
fetal/JJ
DNA/NN
(/(
cffDNA/JJ
)/)
present/JJ
in/IN
maternal/JJ
circulation/NN
and/CC
enables/VBZ
non-invasive/JJ
liquid/JJ
biopsy/NN
,/,
in/IN
contrast/NN
to/TO
invasive/JJ
procedures/NNS
,/,
including/VBG
amniocentesis/NN
and/CC
chorionic/JJ
villus/FW
sampling/NN
./.
====================
Although/IN
it/PRP
is/VBZ
technically/RB
challenging/VBG
to/TO
detect/VB
small/JJ
nucleotide-level/JJ
mutations/NNS
from/IN
cffDNA/JJ
at/IN
the/DT
present/JJ
time/NN
,/,
extensive/JJ
research/NN
in/IN
this/DT
field/NN
has/VBZ
yielded/VBD
potential/JJ
in/IN
tackling/VBG
the/DT
problem/NN
[/(
23/CD
]/)
./.
====================
Despite/IN
these/DT
encouraging/VBG
cases/NNS
,/,
there/EX
are/VBP
wide/JJ
gaps/NNS
between/IN
the/DT
diagnosis/NN
and/CC
treatment/NN
of/IN
ultra-rare/JJ
diseases/NNS
./.
====================
Targeted/VBN
and/CC
tailored/VBD
therapies/NNS
for/IN
ultra-rare/JJ
diseases/NNS
are/VBP
usually/RB
hard/VBP
,/,
mainly/RB
because/IN
of/IN
scarce/NN
treatment/NN
options/NNS
./.
====================
To/TO
fill/RB
these/DT
gaps/NNS
,/,
several/JJ
conditions/NNS
should/MD
be/VB
fulfilled/VBN
./.
====================
First/RB
,/,
the/DT
cost/JJ
of/IN
NGS/NN
should/MD
decrease/VB
further/JJ
./.
====================
As/IN
of/IN
this/DT
writing/VBG
,/,
the/DT
cost/JJ
of/IN
WES/NN
has/VBZ
fallen/VBN
to/TO
under/IN
USD/NN
$/CD
1,000/CD
,/,
which/WDT
is/VBZ
still/RB
a/DT
formidable/JJ
price/RB
for/IN
a/DT
routine/NN
application/NN
in/IN
clinics/NNS
,/,
while/IN
the/DT
usage/NN
of/IN
WGS/NN
may/MD
still/RB
be/VB
impractical/JJ
./.
====================
Second/JJ
,/,
the/DT
sensitivity/NN
and/CC
specificity/NN
of/IN
genetic/JJ
diagnostics/NNS
should/MD
be/VB
improved/VBN
./.
====================
Current/JJ
commercially/RB
available/JJ
exome/DT
capture/NN
kits/NNS
covers/NNS
~99/CD
%/NN
of/IN
the/DT
RefSeq/NN
exome/DT
,/,
and/CC
over/IN
95/CD
%/NN
of/IN
the/DT
targeted/VBN
bases/NNS
are/VBP
covered/VBN
at/IN
least/JJS
eight/CD
times/NNS
with/IN
a/DT
typical/JJ
WES/NN
run/JJ
[/(
24/CD
]/)
,/,
implying/VBG
that/DT
we/PRP
are/VBP
achieving/VBG
fair/JJ
exome/DT
coverage/NN
technically/RB
./.
====================
However/RB
,/,
the/DT
positive/JJ
diagnostic/JJ
rate/NN
of/IN
clinical/JJ
WES/NN
for/IN
Mendelian/JJ
phenotypes/NNS
remains/VBZ
~30/CD
%/NN
[/(
25/CD
]/)
,/,
suggesting/VBG
that/IN
a/DT
substantial/JJ
portion/NN
of/IN
the/DT
remainder/NN
(/(
~70/CD
%/NN
)/)
might/MD
be/VB
caused/VBN
by/IN
variants/NNS
located/JJ
outside/IN
of/IN
exons/NNS
or/CC
are/VBP
not/RB
detectable/JJ
by/IN
WES/NN
./.
====================
Although/IN
the/DT
majority/NN
of/IN
functionally/RB
critical/JJ
and/CC
disease-causing/VBG
mutations/NNS
occurs/VBZ
in/IN
protein-coding/VBG
regions/NNS
,/,
the/DT
vast/JJ
majority/NN
of/IN
the/DT
genome/NN
is/VBZ
non-coding/JJ
and/CC
may/MD
contain/VB
variants/NNS
with/IN
functional/JJ
significance/NN
that/IN
has/VBZ
been/VBN
neglected/VBN
./.
====================
Third/RB
,/,
processes/NNS
of/IN
NGS/NN
data/NNS
generation/NN
should/MD
be/VB
more/RBR
simplified/JJ
./.
====================
Currently/RB
,/,
the/DT
typical/JJ
NGS/NN
pipeline/NN
consists/VBZ
of/IN
library/NN
preparation/NN
,/,
sequencing/NN
,/,
and/CC
multiple/JJ
analysis/NN
steps/NNS
,/,
including/VBG
read/VBN
alignments/NNS
,/,
variant/JJ
calling/JJ
,/,
and/CC
annotation/NN
./.
====================
For/IN
NGS/NN
to/TO
pervade/VB
in/IN
clinical/JJ
practice/NN
,/,
the/DT
processes/NNS
from/IN
DNA/NN
samples/NNS
to/TO
the/DT
final/JJ
results/NNS
should/MD
be/VB
more/RBR
concise/JJ
./.
====================
In/IN
this/DT
context/NN
,/,
nanopore/RB
sequencing/NN
techniques/NNS
,/,
such/JJ
as/IN
MinION/NN
,/,
could/MD
function/VB
as/IN
a/DT
good/JJ
alternative/JJ
to/TO
current/JJ
NGS/NN
technologies/NNS
if/IN
they/PRP
improve/VBP
the/DT
high/JJ
error/NN
rates/NNS
and/CC
relatively/RB
small-scale/JJ
data/NNS
output/RB
[/(
26/CD
]/)
./.
====================
Fourth/DT
,/,
more/RBR
treatment/NN
options/NNS
,/,
such/JJ
as/IN
targeted/VBN
drugs/NNS
and/CC
gene/NN
therapy/NN
strategies/NNS
,/,
should/MD
be/VB
provided/VBN
./.
====================
The/DT
metastatic/JJ
rhabdoid/NN
meningioma/NN
with/IN
a/DT
BRAF/NN
mutation/NN
and/CC
CTLA-4/NN
cases/NNS
mentioned/VBD
above/JJ
are/VBP
rather/RB
exceptional/JJ
cases/NNS
,/,
since/IN
the/DT
genetic/JJ
alterations/NNS
were/VBD
already/RB
targeted/VBN
through/IN
commercially/RB
available/JJ
drugs/NNS
./.
====================
Nevertheless/RB
,/,
the/DT
CTLA-4/NN
case/NN
is/VBZ
a/DT
good/JJ
example/NN
of/IN
drug/NN
repositioning/VBG
,/,
which/WDT
can/MD
be/VB
an/DT
efficient/JJ
option/NN
to/TO
accelerate/VB
treatments/NNS
for/IN
ultra-rare/JJ
diseases/NNS
,/,
given/VBN
its/PRP$
shorter/JJR
development/NN
time/NN
and/CC
lower/JJR
cost/IN
[/(
27/CD
]/)
./.
====================
Although/IN
they/PRP
are/VBP
given/VBN
less/RBR
clinical/JJ
attention/NN
and/CC
researched/VBD
less/RBR
often/RB
,/,
ultra-rare/RB
diseases/NNS
have/VBP
been/VBN
occurring/VBG
constantly/RB
,/,
because/IN
every/RB
new/JJ
baby/NN
will/MD
have/VBP
de/FW
novo/FW
mutations/NNS
in/IN
its/PRP$
genome/NN
,/,
posing/VBG
a/DT
small/JJ
chance/NN
of/IN
the/DT
mutations/NNS
causing/VBG
an/DT
unseen/JJ
phenotype/NN
./.
====================
Thus/RB
,/,
it/PRP
would/MD
be/VB
important/JJ
to/TO
improve/VB
prompt/VBP
and/CC
accurate/VBP
diagnoses/NNS
and/CC
suggest/VBP
appropriate/JJ
treatment/NN
options/NNS
for/IN
ultra-rare/JJ
disease/NN
patients/NNS
./.
====================
Although/IN
we/PRP
still/RB
face/JJ
many/JJ
technical/JJ
difficulties/VBZ
to/TO
addressâ€”such/DT
as/IN
the/DT
high/JJ
price/RB
of/IN
NGS/NN
,/,
imperfect/VBP
NGS/NN
technology/NN
,/,
practical/JJ
complexities/NNS
,/,
and/CC
a/DT
shortage/JJ
of/IN
treatment/NN
optionsâ€”the/DT
several/JJ
cases/NNS
illustrated/VBD
here/RB
demonstrate/VBP
successful/JJ
application/NN
of/IN
NGS-based/JJ
precision/NN
medicine/JJ
for/IN
ultra-rare/JJ
diseases/NNS
,/,
benefiting/VBG
patient/NN
care/JJ
in/IN
the/DT
long/JJ
term/NN
./.
====================
In/IN
the/DT
near/JJ
future/JJ
,/,
NGS/NN
will/MD
be/VB
an/DT
essential/JJ
component/NN
in/IN
precision/NN
medicine/NN
regarding/VBG
its/PRP$
high/JJ
throughput/NN
and/CC
relatively/RB
low/JJ
and/CC
further/RB
decreasing/VBG
cost/JJ
and/CC
the/DT
importance/NN
of/IN
individual/JJ
genomic/JJ
information/NN
for/IN
personalized/VBN
strategies/NNS
./.
====================
Mode/RB
of/IN
inheritance/NN
of/IN
rare/JJ
genetic/JJ
diseases/NNS
that/IN
were/VBD
definitively/RB
diagnosed/VBN
in/IN
a/DT
cohort/JJ
of/IN
developmental/JJ
disorders/NNS
./.
====================
Drawn/JJ
with/IN
data/NNS
adopted/JJ
from/IN
Deciphering/JJ
Developmental/JJ
Disorders/NNS
Study/NN
./.
====================
Nature/NN
2015/CD
;/:
519:223-228/CD
[/(
9/CD
]/)
./.
====================
De/DT
novo/FW
mutation/NN
in/IN
ligand/NN
binding/NN
motif/NN
of/IN
cytotoxic/JJ
T/NN
lymphocyte/NN
antigen/NN
4/CD
(/(
CTLA-4/NN
)/)
./.
====================
Modified/VBN
from/IN
Lee/NNP
et/FW
al/JJ
./.
====================
J/NN
Allergy/NN
Clin/NN
Immunol/NN
2016/CD
;/:
137:327-330/CD
[/(
6/CD
]/)
./.
====================
(/(
A/NN
)/)
Proband-specific/JJ
de/FW
novo/FW
mutation/NN
in/IN
CTLA-4/NN
shown/VBN
in/IN
the/DT
pedigree/NN
./.
====================
(/(
B/NN
)/)
Crystal/JJ
structure/NN
of/IN
CTLA-4/NN
homodimer/NN
(/(
right/JJ
)/)
(/(
Protein/NN
Data/NNS
Bank/NN
[/(
PDB/NN
]/)
ID/NN
:/:
3OSK/NN
)/)
[/(
20/CD
]/)
and/CC
close-up/JJ
view/NN
of/IN
interaction/NN
between/IN
CTLA-4/NN
and/CC
CD80/NN
(/(
left/NN
)/)
(/(
PDB/NN
ID/NN
:/:
1I8L/CD
)/)
[/(
21/CD
]/)
./.
====================
(/(
C/NN
)/)
Models/NNS
of/IN
mutant/JJ
CTLA-4/NN
failing/VBG
to/TO
bind/VB
to/TO
CD80/CD86/NN
and/CC
regulate/VBP
immune/JJ
reactions/NNS
and/CC
rescued/VBD
by/IN
CTLA-4-Ig/NN
(/(
abatacept/IN
)/)
./.
====================
APC/NN
,/,
antigen-presenting/JJ
cell/NN
;/:
Th/NN
cell/NN
,/,
T/NN
helper/NN
cell/NN
./.
====================
Classes/NNS
of/IN
CFTR/NN
mutations/NNS
====================
